Results 101 to 110 of about 12,265,574 (365)

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. [PDF]

, 2018
Background Our objective was to determine patterns of antihypertensive agent use by stage of chronic kidney disease (CKD) and to evaluate the association between different classes of antihypertensive agents with nonrenal outcomes, especially in advanced ...
Johansen, Kirsten L, Ku, Elaine, Lin, Feng, McCulloch, Charles E, Vittinghoff, Eric   +4 more
core  

Relationship between cardiovascular risk and lipid testing in one health care system: a retrospective cohort study. [PDF]

, 2015
BackgroundThe US Preventive Services Taskforce (USPSTF) recommends routine lipid screening beginning age 35 for men [1]. For women age 20 and older, as well as men age 20-34, screening is recommended if cardiovascular risk factors are present.
Anderson, Melissa L, Catz, Sheryl L, Fishman, Paul A, Green, Beverly B, Johnson, Ron L, McClure, Jennifer B, Reid, Robert J   +6 more
core   +1 more source

DNase1 RS1053874 Polymorphism is Associated with Early Neurological Recovery through NET Modulation and with Long‐Term Survival in Ischemic Stroke: A Prospective Cohort Study

Annals of Neurology, EarlyView.
Objective Immunothrombosis contributes to ischemic stroke pathophysiology through neutrophil extracellular trap (NET) formation, which promotes thrombus stabilization and microvascular dysfunction. DNase1 is the principal endonuclease responsible for NET degradation.
B. Díaz‐Benito, P. Calleja, L. Alzamora, A. Ruiz‐García, A. Martínez‐Salio, M. Muñoz‐García, F. Ostos, A. García‐Culebras, A. Moraga, M.A. Moro, I. Lizasoain   +10 more
wiley   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Older people and medication taking behaviour: A review of the literature [PDF]

, 2008
Background: Older people represent a sizeable population of the UK. Many older people receive drug treatment for long term conditions. Adherence with medication is therefore an important clinical, financial and resource intensive concern.
Barber, Belcher, Benson, Benson, Blaxter, Bonner, Butler, Campbell, Carr, Chen, Chin, Cline, Cohen, Conrad, Corlett, De Geest, Dowell, Dunbar-Jacob, Ekman, Griffiths, Harrison, Hughes, Johnson, Kippen, Kjellgren, Kjellgren, Kripalani, Lee, Leventhal, Levy, Lumme-Sandt, Maggi Banning, Maidment, Mallion, Mancia, Mays, McElnay, Phatak, Pound, Pound, Roth, Sackett, Salas, Sale, Scotto, Senior, Struthers, Svensson, Unson, Van der Wal, Veehof, Vermiere, Watson, Zafran   +53 more
core   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Costo del tratamiento antihipertensivo en ancianos ingresados en los servicios de Geriatría y Medicina Interna Cost of antihypertensive treatment in elderly admitted to the services of Geriatrics and Internal Medicine

Medisan, 2011
Se efectuó un estudio descriptivo y transversal de 70 ancianos con hipertensión arterial, ingresados en los servicios de Geriatría y Medicina Interna del Hospital Clinicoquirúrgico "Dr.
Juana Adela Fong Estrada, Eloisa Zayas Esteven, Jacquelin Oliva Fong   +2 more
doaj  

BP Reduction, Kidney Function Decline, and Cardiovascular Events in Patients without CKD. [PDF]

, 2018
BACKGROUND AND OBJECTIVES: In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive systolic BP treatment (target
Dias, C, Leitão, L, Magriço, R, Neves, J, Vieira, M   +4 more
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Pharmacological effects of raas blockade in ischemic nephropathy [PDF]

, 2016
Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio, Cianci, Rosario, Coppolino, Giuseppe, Di Mario, Francesca, Farrah, Tariq E., Fuiano, Giorgio, Gigante, Antonietta, Rivoli, Laura, Rosato, Edoardo   +8 more
core   +1 more source